Nektar(NKTR) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company ended 2025 with $245.8 million in cash and investments and no debt on its balance sheet [16][41] - Revenue for Q4 2025 was $21.8 million, with a full-year revenue of $55.2 million [43] - R&D expenses for Q4 2025 were $29.7 million, totaling $117.3 million for the full year [43] - The net loss for Q4 2025 was $36.1 million, resulting in a basic and diluted net loss per share of $1.78, while the full-year net loss was $164.1 million, or $9.73 per share [43][44] Business Line Data and Key Metrics Changes - The company is focusing on advancing its immunology and inflammation pipeline programs, particularly the Treg biologic, rezpegaldesleukin (REZPEG) [6][7] - Positive results were achieved in phase two studies for REZPEG in atopic dermatitis and alopecia areata, validating its novel regulatory T-cell mechanism [8][10] - The atopic dermatitis market is projected to grow to approximately $35 billion by the mid-2030s, with only 10%-15% of patients currently receiving biologic treatments [11][12] Market Data and Key Metrics Changes - There are over 15 million people in the U.S. with moderate to severe atopic dermatitis, presenting a significant market opportunity [10] - The competitive landscape for late-stage novel mechanisms of action (MOAs) has narrowed, positioning REZPEG favorably [12] - The company anticipates that the atopic dermatitis market will see increased adoption of biologics, with a significant opportunity for REZPEG due to its differentiated efficacy and safety profile [11][12] Company Strategy and Development Direction - The company plans to randomize the first patient in phase three studies for atopic dermatitis in June 2026, with a goal to submit a Biologics License Application (BLA) in 2029 [15][16] - REZPEG is positioned as a potential first-in-class biologic in alopecia areata, with plans to advance into phase three following positive phase two results [29][32] - The company is exploring additional indications for REZPEG, including skin and autoimmune diseases, food allergies, and asthma [36][107] Management's Comments on Operating Environment and Future Outlook - Management highlighted the successful outcomes from phase two studies as a pivotal moment for the company, indicating strong potential for REZPEG in treating inflammatory diseases [8][10] - The management expressed confidence in the differentiated safety profile of REZPEG compared to existing treatments, particularly JAK inhibitors, which have significant safety concerns [13][56] - The company is optimistic about the future growth of the atopic dermatitis market and the potential for REZPEG to capture a significant share due to its unique mechanism of action [11][12][125] Other Important Information - The company raised approximately $476 million in additional net cash through a public offering and an ATM facility, strengthening its balance sheet for future investments [16][41] - The company has established a strong safety database for REZPEG, with over 1,000 patients treated to date [26][41] Q&A Session Summary Question: What type of new data could be seen at the AAD conference regarding the alopecia areata study? - Management indicated that the upcoming presentation will showcase additional effects of treatment with REZPEG and the potential for more patients to achieve SALT 20 responses [48][51] Question: Will the ACQ-5 data be included in the phase three program for atopic dermatitis? - Management confirmed that ACQ-5 will be included in the phase three program, with efforts to include it in the label [61] Question: What is the formulation or device for REZPEG being considered for commercial launch? - The plan is to launch REZPEG in an auto-injector device, with weight-banded dosing for ease of administration [71][72] Question: How does REZPEG differentiate from other approaches in type one diabetes? - Management highlighted that REZPEG offers an outpatient dosing regimen without the need for routine monitoring, contrasting with the more complex administration of existing therapies [108][109]